BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Manfidokimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Manfidokimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06767540-1280@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Manfidokimab: Phase 3 readout est. (NCT06767540)
DESCRIPTION:Manfidokimab\, phase 3\, Atopic Dermatitis.\nStudy: A Clinical 
 Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis\nE
 stimated primary completion: 10 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/manfidokimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06767540
URL:https://assetmemo.bio/drug/manfidokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
